Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 6 Hematologic Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic Syndromes 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 51 fludarabine 37 Dexamethasone 35 venetoclax 30 pembrolizumab 25 Rituximab 21 pomalidomide 18 Lenalidomide 18 Gemcitabine 17 fludarabine phosphate 15 Etoposide 14 Cytarabine 13 daratumumab 12 carfilzomib 11 Temozolomide 11 Injections 10 Cisplatin 10 Calcium Dobesilate 10 glofitamab 9 Nivolumab 9 Bortezomib 9 Azacitidine 9 selinexor 8 Vincristine 8 Immunotherapy, Adoptive 8 Carboplatin 8 obinutuzumab 7 cemiplimab 7 Drug Therapy 7 Bevacizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Homoharringtonine × 1 year × Clear all

NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed

Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡